|
vatalanib
vatalanib
information and resources from the National Cancer Institute
vatalanib
An orally bioavailable anilinophthalazine with potential antineoplastic activity. Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis. This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms. vatalanib
An orally bioavailable anilinophthalazine with potential antineoplastic activity. Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis. This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.
|
|
|
|
|
|
Cancer Treatment Market for Vascular Endothelial Growth Factor ... Nov 29, 2005
PR Newswire (press release), Pharmaceuticals' sorafenib and Pfizer's sutent (sunitinib) for chemotherapy refractory renal cell carcinoma; Novartis/Schering AG's vatalanib for colorectal ...
vatalanib
-->
|
